

20. A process as claimed in claims 17, wherein part c) includes a permeation chromatography step.

21. A process as claimed in claims 17, further comprising an ion exchange step after protease digestion.

22. An inactivated Hepatitis A virus obtained by the process according to claim 17.

23. An inactivated Hepatitis A virus obtained by the process according to claim 21.

24. An inactivated Hepatitis A virus preparation substantially free of host cell contaminants.

25. The inactivated Hepatitis A virus of claim 24, comprising less than 10% or less than 8% or less than 5% contaminating host cell proteins detectable by scanning SDS PAGE.

26. A Hepatitis A vaccine comprising an inactivated Hepatitis A virus according to any one of claims 22 to 25.

27. A vaccine according to claim 26 formulated with a Th1-type inducing adjuvant.

28. A vaccine according to claim 27, wherein the adjuvant comprises monophosphoryl lipid A or a derivative thereof.

29. A vaccine according to claim 28, further comprising QS21.

30. A vaccine according to claim 29, further comprising an oil in water emulsion and tocopherol.

31. A vaccine according to claim 25, further comprising a Hepatitis B antigen.

32. A vaccine according to claim 29, further comprising a Hepatitis B antigen.

33. A vaccine according to claim 30, further comprising a Hepatitis B antigen.